Healthcare stocks were lower pre-bell Tuesday, with the iShares Biotechnology ETF (IBB) and the State Street Health Care Select Sector SPDR ETF (XLV) both down by 1.3%.
Novartis (NVS) was down more than 12% after the company said its phase 3 Harbor study evaluating delpacibart etedesiran in patients with myotonic dystrophy type 1 failed to meet its primary endpoint of video hand opening time.
Boston Scientific (BSX) shares were down more than 1% after the company said it is unlikely to meet its net sales growth and adjusted EPS guidance ranges for Q3 and 2026 due to a cybersecurity incident that led to a global disruption to its operations.
Roivant Sciences' (ROIV) Pulmovant unit's phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease, or PH-ILD, met its primary and secondary endpoints, the company said. Roivant Sciences stock was up more than 17% pre-bell.